公开(公告)号：US20210115020A1

公开(公告)日：2021-04-22

申请号：US17253269

申请日：2019-06-26

Applicant: BIOGEN MA INC.

Inventor： Felix Gonzalez Lopez de Turiso ,  Michael Dechantsreiter ,  Zhili Xin ,  John H. Jones ,  Martin Himmelbauer

IPC: C07D401/14

Abstract: Provided are compounds of Formula (I): including compounds of Formulas (II), (III) and (IV), wherein X, R1, R2, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

公开(公告)号：US20240109867A1

公开(公告)日：2024-04-04

申请号：US18377125

申请日：2023-10-05

Applicant: BIOGEN MA INC.

Inventor： Felix Gonzalez Lopez de Turiso ,  Michael Dechantsreiter ,  Zhili Xin ,  John H. Jones ,  Martin Himmelbauer

IPC: C07D401/14

CPC classification number: C07D401/14

Abstract: Provided are compounds of Formula (I):




including compounds of Formulas (II), (III) and (IV), wherein X, R1, R2, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

公开(公告)号：US10899753B2

公开(公告)日：2021-01-26

申请号：US16410725

申请日：2019-05-13

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Bin Ma ,  Robin Prince ,  Isaac Marx ,  Jürgen Schulz ,  Marta Nevalainen ,  Michael Dechantsreiter

IPC: C07D413/14 ,  C07D403/14 ,  C07D405/14

Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

公开(公告)号：US11814362B2

公开(公告)日：2023-11-14

申请号：US17253269

申请日：2019-06-26

Applicant: BIOGEN MA INC.

Inventor： Felix Gonzalez Lopez de Turiso ,  Michael Dechantsreiter ,  Zhili Xin ,  John H. Jones ,  Martin Himmelbauer

IPC: C07D401/14

CPC classification number: C07D401/14

Abstract: Provided are compounds of Formula (I): including compounds of Formulas (II), (III) and (IV), wherein X, R1, R2, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

公开(公告)号：US20190389836A1

公开(公告)日：2019-12-26

申请号：US16481772

申请日：2018-01-29

Applicant: BIOGEN MA INC.

Inventor： Andrew George Capacci ,  Michael Dechantsreiter ,  Istvan Enyedy ,  John H. Jones ,  Edward Yin-Shiang Lin ,  Brian Stuart Lucas ,  Bin Ma

IPC: C07D401/06 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D215/14 ,  C07D405/14 ,  C07D471/04 ,  C07D451/02

Abstract: Provided are tetrahydroisoquinoline derivatives as Nrf2 activators.

公开(公告)号：US20190382394A1

公开(公告)日：2019-12-19

申请号：US16410725

申请日：2019-05-13

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Bin Ma ,  Robin Prince ,  Isaac Marx ,  Jürgen Schulz ,  Marta Nevalainen ,  Michael Dechantsreiter

IPC: C07D413/14 ,  C07D405/14 ,  C07D403/14

Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.